Centre-based Evaluation of Heamatological and Some Biochemical Effects of the Initial Phase of Anti-tuberculosis Therapy in Bayelsa State

Centre-based Evaluation of Heamatological and Some Biochemical Effects of the Initial Phase of Anti-tuberculosis Therapy in Bayelsa State

The aim of this study was to determine the adverse effects of anti-tuberculosis drugs on blood and some biochemical parameters in patients with primary tuberculosis infection.

Study Design: This study used a non-probability (purposive) sampling method.

The research was performed at the Tuberculosis and Leprosy Referral Hospital’s Chest Clinic in Yenagoa, Bayelsa State, Nigeria. From July 2017 to April 2018, this research was carried out.

Methodology: Tuberculosis patients were detected using normal clinical diagnostic methods and confirmed in the laboratory using acid quick bacilli as a preliminary test and Gene-Xpert® as a confirmatory test for Mycobacterium tuberculosis. At the Tuberculosis and Leprosy Referral Hospital in Yenegoa, Bayelsa State, 44 tuberculosis patients met the study’s inclusion and exclusion requirements and completed the study. For two months, qualifying patients were given the required daily dose of a single drug combination (rifampicin-150 mg, isoniazid-75 mg, pyrazinamide-400 mg, and ethambutol-275 mg) based on their bodyweight. At baseline, week 4, and week 8, blood was drawn and checked for complete blood count, liver enzymes, Alkaline phosphatase (ALP), Alanine transaminase (ALT), Aspartate aminotransferase (AST), Total proteins, Bilirubin, and Cholesterol. Using a statistical kit for social sciences, the data were descriptively analysed (SPSS 21).

Results: During the intensive therapy process, alanine aminotransferase and alkaline phosphatase levels significantly increased (P=0.5). Total cholesterol and albumin levels both decreased dramatically (P=0.5). The WBC was also significantly lower (P0.05) in week 0 (12.451.35), week 4 (8.930.42), and week 8 (7.700.34), while the RBC was significantly higher (P0.05); RBC: week 0 (4.020.12), week 4 (4.590.12), and week 8 (4.820.10). There were no major increases in aspartate aminotransferase, total protein, or total bilirubin, and haematological changes were observed, but they were not serious enough to cause the therapy to be stopped.

Conclusion: The study’s findings indicated improvements in full blood count and certain biochemical parameters, but not to the degree that therapy should be stopped.

Author (s) Details

Bonsome Bokolo
Department of Pharmacology, Faculty of Basic Medical Sciences, Niger Delta University, Bayelsa State, Nigeria.

Ozakieoniso James Kemelayefa
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Niger Delta University, Bayelsa State, Nigeria.

Ozakieoniso James Kemelayefa
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Niger Delta University, Bayelsa State, Nigeria.

Prof. Fidelis Ching Poh
Department of Pharmacology, Faculty of Basic Medical Sciences, Niger Delta University, Bayelsa State, Nigeria.

View Book :- https://stm.bookpi.org/TIPR-V1/issue/view/38

Editor 251News

Related Posts

leave a comment

Create Account



Log In Your Account